|1.||Donahoe, Patricia K: 15 articles (08/2015 - 01/2002)|
|2.||MacLaughlin, David T: 13 articles (05/2015 - 01/2002)|
|3.||Kim, Jang Heub: 6 articles (05/2015 - 06/2009)|
|4.||Kim, Mee Ran: 5 articles (05/2015 - 06/2009)|
|5.||Pieretti-Vanmarcke, Rafael: 4 articles (01/2011 - 03/2006)|
|6.||Song, Jae Yen: 3 articles (09/2012 - 06/2009)|
|7.||Ryu, Ki Sung: 3 articles (06/2012 - 06/2009)|
|8.||Donahoe, P K: 3 articles (03/2005 - 09/2000)|
|9.||Maheswaran, S: 3 articles (03/2005 - 09/2000)|
|10.||Maheswaran, Shyamala: 3 articles (12/2003 - 01/2002)|
|1.||Ovarian Neoplasms (Ovarian Cancer)
01/01/2008 - "The expression of the MIS type II receptor (MISRII) in ovarian cancer cells and the ability of MIS to inhibit proliferation of these cells suggest that MIS might be a promising therapeutic for recurrent ovarian cancer. "
11/01/1999 - "Solid ovarian cancers were positive for the MIS type II receptor protein by immunohistochemical staining, which colocalized with staining for antibody to CA-125 (OC-125). "
09/01/2014 - "These findings indicate that bioactive MIS/AMH recombinant protein should be tested in patients against tumors expressing the MIS/AMH receptor complex, perhaps beginning with ovarian cancer because it has the worst prognosis. "
11/14/2006 - "Mullerian Inhibiting Substance (MIS), a biological modifier that causes regression of Mullerian ducts in male embryos, is effective as a single agent in vitro and in vivo against human and mouse ovarian cancer cell lines expressing MIS type II receptor; however, little is known about how recombinant human MIS (rhMIS), now being scaled for preclinical trials, could be used in combination with cytotoxic or targeted chemotherapeutic agents. "
03/01/2006 - "Recombinant human Mullerian inhibiting substance inhibits long-term growth of MIS type II receptor-directed transgenic mouse ovarian cancers in vivo."
10/01/2011 - "In this study, we demonstrated the expression of MIS type II receptor (MISRII) in the human papillomavirus (HPV)-16-related cervical cancer cell lines CaSki and SiHa, and a non-HPV-related cervical cancer cell line, C33A. "
08/11/2015 - "Finally, we tested the frequency of MIS type II receptor expression in a tissue microarray of serous ovarian tumors by immunohistochemistry and found that 88% of patients bear tumors that express the receptor. "
09/01/2014 - "The molecular tools to identify MIS/AMH receptor expressing ovarian and other cancers are in place, thus, it is possible to select patients for treatment. "
11/01/2011 - "Both AMH and AMH receptor (AMHR2) immunolabeling and expression were detected by immunohistochemistry in the tumor and cyst fluid obtained from mares with GCTs. "
01/01/2011 - "MIS, at concentrations below those that inhibit cell proliferation, blocked in vitro invasion and in vivo migration of epithelial cancer cells that express the MIS receptor. "
|3.||Endometrial Neoplasms (Endometrial Cancer)
05/01/2015 - "In the present study we show that MIS type II receptor was highly expressed in AN3CA cells, a cell line derived from human endometrial cancer cell in which MIS-treatment caused a reduction of cell viability, and induced cellular apoptosis and genes involved cell cycle arrest. "
01/04/2005 - "Here, we show that both normal human endometrium and endometrial cancers express the receptor for MIS and that MIS can inhibit the proliferation of a number of human endometrial cancer cell lines that express the MIS type II receptor. "
02/01/2015 - "Our aim was to evaluate serum levels of anti-Müllerian hormone (AMH) and also immunohistochemical (IHC) staining properties of AMH receptor type II (AMHRII) in patients with endometrial cancer (EC) and a control group. "
|4.||Primary Ovarian Insufficiency
09/01/2012 - "Our objective was to investigate the expression of MIS type II receptor (MISR II) and whether MIS can inhibit the proliferation and induce apoptosis in primary cultures of endometrial stromal cells (ESC) of endometriosis. "
09/01/2014 - "Furthermore, several lines of evidence suggest that MIS/AMH inhibits proliferation in tissues and cell lines of other MIS/AMH receptor-expressing gynecologic tumors such as cervical, endometrial, breast, and in endometriosis as well. "
05/01/2014 - "To evaluate antimüllerian hormone (AMH) and AMH receptor II (AMHRII) mRNA and protein expression in endometrium and in ovarian or deep lesions of women with endometriosis. "
|2.||Messenger RNA (mRNA)
|4.||Tumor Viral Antigens (Large T Antigen)
|5.||Protein Isoforms (Isoforms)
|8.||Persistent Mullerian duct syndrome